Table 3 Summary of placental transfer and mammary excretion of various angiotensin receptor blockers
From: Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats
Disposition site | Drug | Dose (mg/kg) | Route | Gestation or Lactation day | Time after dose | Maternal Plasma conc. (PL) | Milk (MI) or Fetus (FE) conc. | KP % (MI/PL or FE/PL) | Reference |
|---|---|---|---|---|---|---|---|---|---|
Fetus | Losartan | 135 | P.O. (Multiple) | 6 ~ 15 | – | 88a (μg · hr/mL) | – | – | [17] |
15 ~ 20 | – | 194.8a (μg · hr/mL) | 50.7a (μg · hr/mL) | 26.0 | |||||
Telmisartan | 1 | P.O. | 12 | 4 | 43.56 (ng-eq/mL) | 11.83 (ng-eq/g) | 27.2 | ||
12 | 8 | 34.47 (ng-eq/mL) | 11.03 (ng-eq/g) | 32.0 | |||||
12 | 24 | 5.98 (ng-eq/mL) | 7.98 (ng-eq/g) | 133.4 | |||||
12 | 48 | 3.65 (ng-eq/mL) | 1.89 (ng-eq/g) | 51.8 | |||||
18 | 4 | 77.05 (ng-eq/mL) | 13.72 (ng-eq/g) | 17.8 | |||||
18 | 24 | 19.73 (ng-eq/mL) | 45.27 (ng-eq/g) | 229.4 | |||||
18 | 48 | 9.01 (ng-eq/mL) | 17.65 (ng-eq/g) | 195.9 | |||||
Olmesartan | – | P.O. | 18 | – | – | – | >100 | [19] | |
Valsartan | 600 | – | 18 | 1 | 7 ~ 9 (μg-eq/g) | 4 ~ 5 (μg-eq/g) | 56.0 | [20] | |
18 | 24 | NDb | 3 ~ 4 (μg-eq/g) | – | |||||
Milk | Losartan | 135 | P.O. (Multiple) | 7 | – | 3.86 (μg/mL) | 1.16 (μg/mL) | 30.1 | [17] |
14 | – | 3.00 (μg/mL) | 1.96 (μg/mL) | 65.3 | |||||
21 | – | 3.14 (μg/mL) | 1.71 (μg/mL) | 54.5 | |||||
Telmisartan | 1 | P.O. | – | 0.5 | 23.77 (ng-eq/mL) | 3.32 (ng-eq/mL) | 14.0 | ||
2 | 31.04 (ng-eq/mL) | 30.6 (ng-eq/mL) | 98.6 | ||||||
4 | 34.84 (ng-eq/mL) | 54.24 (ng-eq/mL) | 155.7 | ||||||
8 | 36.12 (ng-eq/mL) | 66.08 (ng-eq/mL) | 182.9 | ||||||
24 | 9.3 (ng-eq/mL) | 13.52 (ng-eq/mL) | 145.4 | ||||||
48 | 4.06 (ng-eq/mL) | 6.79 (ng-eq/mL) | 167.2 | ||||||
Olmesartan | – | P.O. | – | 72 | – | – | 25.0 | [19] | |
Valsartan | 600 | – | – | – | – | NDb | – | [20] |